Immix Biopharma, Inc. (NASDAQ:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting
Roper Technologies (NASDAQ: ROP) beat revenue and EPS estimates in Q1 2024, with a 14% Y/Y revenue growth and increased profits. FY24 outlook positive.
Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory